symptom management of therapy-related toxicities
TRANSCRIPT
![Page 1: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/1.jpg)
Symptom Management of Therapy-Related Toxicities
Charles L Loprinzi MDRegis Professor of Breast Cancer OncologyMayo Clinic Rochester, MN
![Page 2: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/2.jpg)
Conflicts-donations to Mayo
• Pfizer -pregabalin to prevent paclitaxel-induced neuropathy
• Competitive Technologies- donated a Scrambler machine
![Page 3: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/3.jpg)
Issues•Hot Flashes•Vaginal Dryness•AI arthralgias•Paclitaxel neuropathy
![Page 4: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/4.jpg)
Basic Study Design
Eligible Patients Stratify Randomize
Double Blind
Agent
Placebo
![Page 5: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/5.jpg)
Mean Hot Flash Score Reduction Randomized Studies
0
20
40
60
80
100
0 1 2 3 4 5 6
Week
% R
educ
tion
(Mea
n) Placebo (n=420)Soy (n=78)
Clonidine (n=75)
Megestrol (n=74)
Fluoxetine (n=36)
Venlafaxine (n=48)
Vitamin E (n=53)
![Page 6: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/6.jpg)
Mean Hot Flash Score Reduction Randomized Studies
0
20
40
60
80
100
0 1 2 3 4 5 6
Week
% R
educ
tion
(Mea
n) Placebo (n=420)Soy (n=78)
Clonidine (n=75)
Megestrol (n=74)
Fluoxetine (n=36)
Venlafaxine (n=48)
Vitamin E (n=53)
Black Cohosh (n=58)
Ven (vs MPA) (n=94)
MPA 400 mg (n=94)
MPA 500 mg X 3(n=7)
Pregabalin (n=63)
Citalopram (n=57)
Flaxseed (n=69)
![Page 7: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/7.jpg)
Mean Hot Flash Score Reduction Randomized Studies
0
20
40
60
80
100
0 1 2 3 4 5 6
Week
% R
educ
tion
(Mea
n) Placebo (n=420)Soy (n=78)
Clonidine (n=75)
Megestrol (n=74)
Fluoxetine (n=36)
Venlafaxine (n=48)
Vitamin E (n=53)
Black Cohosh (n=58)
Ven (vs MPA) (n=94)
MPA 400 mg (n=94)
MPA 500 mg X 3(n=7)
Pregabalin (n=63)
Citalopram (n=57)
Flaxseed (n=69)
![Page 8: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/8.jpg)
Hot Flash Topics• Overview of Mayo/NCCTG Randomized
Hot Flash Studies• Newer antidepressant meta-analysis• CYP 2D6/Tamoxifen metabolism• Gabapentin meta-analysis• Gabapentin vs venlafaxine
![Page 9: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/9.jpg)
CP1274470B-23
-70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70Favors antidepressant Favors placebo
Loprinzi, Fluoxetine 20 mg/g
HR (fixed)95% CIStudy
Stearns, Paroxetine 10 mg/dStearns, Paroxetine 20 mg/dStearns, Paroxetine 12.5 mg/dStearns, Paroxetine 25 mg/dParoxetine total
Gordon, Sertraline 50 mg/dKimmick, Sertraline 50 mg/dGrady, Sertraline 100 mg/dSertraline total
Loprinzi, Venlafaxine 37.5 mg/dLoprinzi, Venlafaxine 75 mg/dLoprinzi, Venlafaxine 150 mg/dVenlafaxine total
Antidepressants total
Loprinzi CL et al J Clin Oncol 2009, 27(17); 2831-37.
![Page 10: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/10.jpg)
Are there other placebo-controlled trials published after this meta-analysis?
![Page 11: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/11.jpg)
Subsequent Placebo-controlled Hot Flash
Antidepressant Studies with Similar Outcomes
• Desvenlafaxine• Citalopram• EscitalopramBarton DL, et al; J Clin Oncol. 2010 Jul 10;28(20):3278-83Archer DF, et al; Am J Obstet Gynecol. 2009; 200(3):238Freeman, et al; JAMA 2011; 305; 267-74Speroff L, et al; Obstet Gynecol. 2008;111(1):77-87.
![Page 12: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/12.jpg)
Hot Flash Topics• Overview of Mayo/NCCTG Randomized
Hot Flash Studies• Newer antidepressant meta-analysis• CYP 2D6/Tamoxifen metabolism• Gabapentin meta-analysis• Gabapentin vs venlafaxine
![Page 13: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/13.jpg)
JNCI 2003;95;1758-64
![Page 14: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/14.jpg)
CYP 2D6 Websites
• Google- ‘CYP 2D6 inhibitors’• http://medicine.iupui.edu/clinpharm/d
dis/table.asp
![Page 15: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/15.jpg)
Hot Flash Topics• Overview of Mayo/NCCTG Randomized
Hot Flash Studies• Newer antidepressant meta-analysis• CYP 2D6/Tamoxifen metabolism• Gabapentin meta-analysis• Gabapentin vs venlafaxine
![Page 16: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/16.jpg)
CP1274470B-22
Favors gabapentin Favors placebo
-70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70
Pandya 300 mg/d
Pandya 900 mg/d
Guttuso 900 mg/d
Reddy 2400 mg/d
Total
HR (fixed)95% CIStudy
Loprinzi CL et al J Clin Oncol 2009, 27(17); 2831-37.
![Page 17: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/17.jpg)
0
20
40
60
80
100
Pregabalin Median Hot Flash ScoreR
educ
tion
from
bas
elin
e (%
)
Week
Baseline 1 2 3 4 5 6
Pregabalin 150 mg bidPregabalin 75 mg bid
Placebo
P= 0.002 (75 bid)
P= 0.007 (150 bid)
Loprinzi CL, et al JCO 2010 28(4):651-7.
![Page 18: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/18.jpg)
CP1274470B-22
Favors gabapentin Favors placebo
-70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 60 70
Pandya 300 mg/d
Pandya 900 mg/d
Guttuso 900 mg/d
Reddy 2400 mg/d
Total
HR (fixed)95% CIStudy
Pregabalin
![Page 19: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/19.jpg)
Hot Flash Topics• Overview of Mayo/NCCTG Randomized
Hot Flash Studies• Newer antidepressant meta-analysis• CYP 2D6/Tamoxifen metabolism• Gabapentin meta-analysis• Gabapentin vs venlafaxine
![Page 20: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/20.jpg)
Which do patients prefer better, gabapentin or venlafaxine?
![Page 21: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/21.jpg)
A randomized crossover trial of venlafaxine versus gabapentin for hot flashes in breast cancer
survivors
Louise Bordeleau Olivera Jugovic Kathleen Pritchard Marguerite Ennis David Warr Rashida Haq Charles Loprinzi Pamela Goodwin
JCO 28; #9023; ASCO, 2010
![Page 22: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/22.jpg)
Study schema: Crossover RCT
Venlafaxine
Gabapentin Gabapentin
Venlafaxine
Screening
2 weeks
Randomization Venlafaxine: 37.5mg daily X 7d 75mg dailyGabapentin: 300mg daily X 3d
300 mg BID X 3d 300mg TID
4 weeks 2 – 4 weeks 4 weeks
![Page 23: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/23.jpg)
Overall Efficacy
Week
Mea
n of
dai
ly h
ot fl
ash
scor
es
2 4 6 8 10 12
05
1015
2025
VV
V V
G
GG G
G
G G G
V
V V V
![Page 24: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/24.jpg)
Patient Preference
• Number of preference forms completed: 58 - Did not prefer one drug over another: 2- Expressed a preference: 56
• Patients with a preference: 56- Preferred venlafaxine: 38 (68%)- Preferred gabapentin: 18 (32%) P=0.01
![Page 25: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/25.jpg)
Issues•Hot Flashes•Vaginal Dryness•AI arthralgias•Paclitaxel neuropathy
![Page 26: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/26.jpg)
Vaginal Dryness
The reported incidence of vaginal dryness was 36-71% in two studies that looked at menopausal symptoms in breast cancer survivors.
Ganz PA, et al: J Natl Cancer Inst 92:1054-64, 2000.Knobf MT: Cancer Nurs 24:201-10; quiz 210-1, 2001.
![Page 27: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/27.jpg)
Vaginal Dryness
• Non-estrogenic vaginal lubricants
• Vaginal estrogen• DHEA
![Page 28: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/28.jpg)
Loprinzi et al JCO 15: 969-973, 1997
![Page 29: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/29.jpg)
Vaginal Dryness
• Non-estrogenic vaginal lubricants
• Vaginal estrogen• DHEA
![Page 30: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/30.jpg)
Vaginal estrogen appears to work better than does
Replens.
Nachtigall LE: Comparative study: Replens versus local estrogen inmenopausal women. Fert Steril 61:178-180, 1994.
Bygdeman M, Swahn ML: Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23:259-263, 1996.
![Page 31: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/31.jpg)
Is there concern regarding vaginal estrogen use with AIs?
![Page 32: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/32.jpg)
The Effects of Vaginal Estrogens (VE) on Serum Estradiol Levels Breast Cancer Survivors Receiving an Aromatase Inhibitor (AI) or a
Selective Estrogen Receptor Modulator (SERM)
S Wills, A Ravipati P Venuturumilli, C Kresge, E Folkerd, M Dowsett, D
Hayes, D Decker
SABCS; 2009
![Page 33: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/33.jpg)
Objective• Determine the degree of estrogen
absorption from• Chronic E2 tablet • Estrogen ring
• Postmenopausal breast cancer survivors• Adjuvant AI • Adjuvant SERM
![Page 34: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/34.jpg)
Cases and Controls
• Postmenopausal women• No menstrual period for 1 year, or • Oophorectomy• ER positive breast cancer
• Completed• Local breast cancer therapy • Systemic chemotherapy
• Clinically NED• Using a VE for atrophic vaginitis
![Page 35: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/35.jpg)
Cases
• 14 Patients using E2 tablet• 1 tablet inserted 2 x per week ≥ 3 months
• 10 Patients using E2 ring • Ring inserted once every 90
days ≥ 3 months
![Page 36: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/36.jpg)
Controls
• 24 postmenopausal breast cancer survivors
• After local therapy and/or chemotherapy
• Receiving an AI or SERM as adjuvant therapy
• Not on E2 tablet or ring
![Page 37: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/37.jpg)
Controls on AI Only
![Page 38: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/38.jpg)
Cases Using E2 Ring:AI or SERM
![Page 39: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/39.jpg)
Cases Using E2 Tablet:AI or SERM
![Page 40: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/40.jpg)
Vaginal Dryness
• Non-estrogenic vaginal lubricants
• Vaginal estrogen• DHEA
![Page 41: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/41.jpg)
Menopause; Vol 16 #5
• Intravaginal dehydroepiandrosterone, a physiologic and highly efficient treatment of vaginal atrophy
• Labrie, et al
![Page 42: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/42.jpg)
Menopause; Vol 16 #5
• Effect of intravaginal dehydroepiandrosterone on libido and sexual dysfunction in postmenopausal women
• Labrie, et al
![Page 43: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/43.jpg)
Menopause; Vol 16 #5
• Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration
• Labrie, et al
![Page 44: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/44.jpg)
Menopause; Vol 16 #5
• Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: Hormone Precursor Replacement Therapy (HPRT)
• Editorial
![Page 45: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/45.jpg)
Vaginal DHEA For Vaginal Symptoms:
A Phase III Randomized, Double Blind, Placebo-Controlled Study
Debra Barton, et al
![Page 46: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/46.jpg)
Women with cancer and vaginal dryness
Randomize
Placebo DHEA 0.25% 3.25 mgvaginally X 12 W
DHEA 0.25% 6.5 mgvaginally X 12 W
![Page 47: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/47.jpg)
Issues•Hot Flashes•Vaginal Dryness•AI arthralgias•Paclitaxel neuropathy
![Page 48: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/48.jpg)
What is the natural history of AI arthralgias?
![Page 49: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/49.jpg)
Aromatase Inhibitor Arthralgias
• Large early trials• Incidence ~5-20%
• Patients report : “I feel like an old lady”• True incidence is probably ~50%• ~10-20% discontinue therapy because of
toxic effects• Usually with symptom resolution
Crew…Hershman, JCO 2007
![Page 50: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/50.jpg)
Prevalence of joint symptoms in women on AI’s for early stage BC
• Cross-sectional survey of 200 consecutive pts receiving adjuvant AI therapy
• Self-administered 25-item survey
Crew…Hershman, JCO 2007
![Page 51: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/51.jpg)
Location of Joint Symptoms
60
0
10
40
50
% o
f Pat
ient
s W
ith A
I-Rel
ated
Join
t Sym
ptom
s
20
30
Hands Knees Back
PainStiffness
Crew…Hershman, JCO 2007
![Page 52: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/52.jpg)
Severity of Joint Symptoms
60
0
10
40
50
Mild(1-4)
% o
f Pat
ient
s W
ith A
I-Rel
ated
Join
t Sym
ptom
s
20
30
Moderate(5-7)
Severe(6-10)
PainStiffness
Crew…Hershman, JCO 2007
![Page 53: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/53.jpg)
Are there any promising appearing therapies for AI arthralgias?
![Page 54: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/54.jpg)
Promising-Appearing Study Ideas
•Acupuncture•Testosterone•Omega 3 FA•Vitamin D
![Page 55: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/55.jpg)
Randomized Placebo-Controlled Trial of Acupuncture for AI-related Joint Symptoms
Eligibility:
•Postmenopausal•Adjuvant AI for > 6 mo•Worst joint pain score ≥ 3•N=40
RANDOMIZE
Sham Acupuncture twice weekly x 6wks
Acupuncture twiceweekly x 6wks
Primary Outcome: Change in joint pain score (BPI-SF)
Crew…Hershman et al. JCO MAR 1, 2010:1154
![Page 56: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/56.jpg)
Percent change in the group mean Brief Pain Inventory–Short Form (BPI-SF) scores from baseline to 3 and 6 weeks for the true and sham acupuncture groups: (A) BPI-SF worst pain,
(B) BPI-SF pain severity, and (C) BPI-SF pain-related interference.
Crew K D et al. JCO 2010;28:1154-1160
©2010 by American Society of Clinical Oncology
![Page 57: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/57.jpg)
Acupuncture
Multi-institutional confirmatory trial underway
![Page 58: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/58.jpg)
Promising-Appearing Study Ideas
•Acupuncture•Testosterone•Omega 3 FA•Vitamin D
![Page 59: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/59.jpg)
Testosterone undecanoate treatment reduces joint morbidities induced by
anastrozole therapy in postmenopausal women with breast
cancer: results of a double-blind, randomized phase II trial
Birrell SN and Tilley WD.
Australia
![Page 60: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/60.jpg)
Trial Design
30=placebo 30= 40mg TU 30= 80mg TU
3 months of placebo or testosterone undecoanate (TU)
90 women on adjuvant anastrozole1mg per day plus
![Page 61: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/61.jpg)
0%
20%
40%
60%
80%
100%
Baseline1 month3 months
P=0.04
Placebo 40 mg TU 80 mg TU
Percentage of patients with a PAIN VAS >50mm
![Page 62: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/62.jpg)
Placebo 40 mg TU 80 mg TU
Percentage of patients with a Stiffness VAS >50mm
0%
20%
40%
60%
80%
100%
Baseline1 month3 months
P=0.06
![Page 63: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/63.jpg)
0
10
20
30
40
50
60
Baseline1 month3 months
Placebo 40 mg TU 80 mg TU
Estradiol concentrations
![Page 64: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/64.jpg)
Placebo 40 mg TU 80 mg TU
Free Testosterone Concentrations
0
2
4
6
8
10
12
Baseline1 month3 months
![Page 65: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/65.jpg)
A randomized double-blind placebo controlled, Phase II/III, study of
aromatase inhibitors and transdermal testosterone in the adjuvant treatment
of postmenopausal women with aromatase inhibitor induced
arthralgias: N10C7
Stephen Birrell, M.D. Ph.D.
Charles Loprinzi, M.D.
![Page 66: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/66.jpg)
Randomized Placebo-Controlled Trial of Testosterone for AI-related Joint Symptoms
Eligibility:
•Postmenopausal•Adjuvant AI•Worst joint pain score ≥ 50/100
RANDOMIZE
Placebo
Subcutaneous Testosterone
Primary Outcome: Change in joint pain score at 3 mos
N=226
![Page 67: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/67.jpg)
Promising-Appearing Study Ideas
•Acupuncture•Testosterone•Omega 3 FA•Vitamin D
![Page 68: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/68.jpg)
S0927:Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the control of Aromatase Inhibitor-Induced
Musculoskeletal Pain in Women with Early Stage Breast Cancer
Eligibility:Age > 21 yearsPostmenopausalStage I-III ER+ and/or PR+
breast cancerTaking an AI for > 3 moWorst joint pain score ≥ 5N=~246
RANDOMIZE
Follow-up: 0, 6, 12, 24 weeks
Primary Endpoint: Change in worst joint pain/stiffness at 12 weeks
Placebox 24 wks
Omega 3 Fatty Acidx 24 wks
Stratification: history osteoarthritis and prior taxane use
![Page 69: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/69.jpg)
Promising-Appearing Study Ideas
•Acupuncture•Testosterone•Omega 3 FA•Vitamin D
![Page 70: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/70.jpg)
The VITAL trialRandomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with
breast cancer starting adjuvant letrozole.
Qamar J. KhanBruce F. KimlerPavan S. Reddy
Priyanka SharmaJennifer R. Klemp
Carol J. Fabian
The University of Kansas Medical CenterCancer Center of Kansas, Wichita KS
ASCO 2012 Abstract # 9000
![Page 71: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/71.jpg)
Postmenopausal stage I-III breast cancer starting adjuvant Letrozole
25OHD levels 40 ng/ml or less
Schema
Vit D3 30,000 IU/wk
RDA of Ca + D
Matching placebo/wk
RDA of Ca + D 24 weeks
80 80
Randomized, double-blind, placebo-controlled
![Page 72: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/72.jpg)
Freq
uenc
y of
MS
even
t, %
P=0.069
51%37%
Primary Endpoint (protocol defined): Incidence of a MS Event using Simple Descriptive Pain Intensity Scale*
*Worsening pain (Simple Descriptive Pain Intensity Scale), worsening disability (HAQ II), or discontinuation of letrozole due to musculoskeletal pain
![Page 73: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/73.jpg)
Vitamin D
• Phase III trial in development, by verbal report
![Page 74: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/74.jpg)
What is the current recommended treatment for AI arthralgias?
![Page 75: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/75.jpg)
Current Recommendations
• Try analgesics, exercise• If the patient is having substantial
trouble, stop the AI and give a few weeks to resolve
• Consider re-starting another AI• Consider tamoxifen• Re-consider magnitude of benefit of
adjuvant hormonal therapy
![Page 76: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/76.jpg)
Issues•Hot Flashes•Vaginal Dryness•AI arthralgias•Paclitaxel neuropathy
![Page 77: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/77.jpg)
Topics
• Natural history investigation results
• Important clinical study results
![Page 78: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/78.jpg)
Introduction
• Paclitaxel infusion commonly is followed, in 2-4 days, by an acute pain syndrome, with symptoms usually resolving in 3-7 days
• This pain has been called paclitaxel-induced arthralgia or myalgia
CP1347589-78
![Page 79: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/79.jpg)
CP1347589-79
![Page 80: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/80.jpg)
The Paclitaxel Acute Pain Syndrome: Sensitization of Nociceptors as the Putative
Mechanism
Loprinzi et al: J Cancer 13(6):399, 2007
CP1347589-80
![Page 81: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/81.jpg)
Patients scheduled to receive IV paclitaxel at one of 2 dose/schedules175+ mg/m2 Q 3 wks70-90 mg/m2 weekly
Patient questionnaires looking at the incidence and severity of paclitaxel-associated acute pain and sensory neuropathy.
Paclitaxel-Associated Acute Pain Syndrome: Natural History Study
N08C1
![Page 82: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/82.jpg)
P-APS Data
![Page 83: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/83.jpg)
10
0
1
2
3
2 3 4 5 6 7
Worst P-APS Scores for Cycle 1(Weekly)
n= 91 91 90 91 91 90Time (Days)
Wor
st P
ain
Scor
e (m
ean)
![Page 84: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/84.jpg)
Mea
n P-
APS
Pai
n
2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7 2 3 4 5 6 7
Cycle 1 Cycle 2 Cycle 3 Cycle 4Day Day Day Day
5
0
234
1
6789
10
Worst P-APS Scores Per Cycle (Q 3 Weeks)
Worst P-APS Scores Per Cycle (Q 3 Weeks)
![Page 85: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/85.jpg)
Daily Mean Pain Scores (Q 3 Week)
Mea
n P-
APS
Pai
n
2 3 4 5 6 7 *2 3 4 5 6 7 2 3 4 5 6 7
*Cycle 4, day 2
Cycle 1 Cycle 2 Cycle 3Day Day Day
0
1-4
5-6
7-10
5
0
234
1
6789
10
![Page 86: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/86.jpg)
![Page 87: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/87.jpg)
Analgesic Use(Weekly)
n= 91 89 85 87 88 85 85 82 79 73 67 59
Cycles
50
0
20
30
1 2 3 4 5 6 7 8 9 10 11 12
40
10
OTC meds
Opioids
Patie
nts
(%)
![Page 88: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/88.jpg)
1 2 3 4 5 6
Analgesic Use(Q 3 Weeks)
Cycles
OTC meds
Opioids
Patie
nts
(%)
70
0
20
30
50
10
60
40
![Page 89: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/89.jpg)
CIPN Data
![Page 90: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/90.jpg)
0
60
80
100
1 2 3 4 5 6 7 8 9 10 11 12
EORTC CIPN-20 Data (Weekly)
Cycles
Bas
elin
e va
lues
(%)
40
0
n= 100 99 95 98 98 96 95 95 93 93 93 91 94n= 100 99 98 98 96 95 94 93 91 90 90 89 88n= 100 98 96 94 92 90 87 85 83 80 80 77 76
Sensory
AutonomicMotor90
70
50P< 0.0001
![Page 91: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/91.jpg)
100
0
40
50
60
70
0 6 9 12 15 18
80
90
3
EORTC CIPN-20 Sensory, Motor and Autonomic Scores (Q 3 Weeks)
n= 81 60 60 54 45 31 29n= 81 67 67 59 49 33 27n= 81 67 67 59 49 33 27
Weeks
CIP
N-2
0 Sc
ores
Autonomic
Motor
Sensory
![Page 92: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/92.jpg)
• Did you have tingling fingers or hands?• Did you have tingling toes or feet?• Did you have numbness in your fingers or hands?• Did you have numbness in your feet or toes?• Did you have shooting or burning pain in your fingers or
hands?• Did you have shooting or burning pain in your toes or
feet?
Individual questions from the CIPN20 sensory subscale used for this analysis
![Page 93: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/93.jpg)
100
0
40
50
60
70
0 2 3 4 5 6 7 8 9 10 11 12
80
90
1
EORTC CIPN-20 Tingling, Numbness and Pain Scores – Hands (Weekly)
n= 91 85 83 80 87 87 84 84 77 79 70 66 58n= 91 85 83 80 87 87 83 84 77 79 70 66 57n= 91 85 83 80 87 87 84 84 77 79 70 66 58
Cycles
Numbness
Pain
Tingling
CIP
N-2
0 Sc
ores
![Page 94: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/94.jpg)
EORTC CIPN-20 Tingling, Numbness and Pain Scores – Hands (Q 3 Weeks)
Weeks
CIP
N-2
0 Sc
ores
0 6 9 12 15 183
n= 81 67 67 58 49 32 28n= 81 67 67 59 49 33 27n= 81 67 66 59 49 33 28
100
0
40
50
60
70
80
90
Numbness
Pain
Tingling
![Page 95: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/95.jpg)
0 2 3 4 5 6 7 8 9 10 11 121
CIPN-20 Burning/Shooting Pain Scores Segregated by Cycle-1 P-APS Scores – Feet
(Weekly)
Cycles
CIP
N-2
0 Pa
in S
core
sP-APS score 0-4
P-APS score 5-10
100
0
40
50
60
70
80
90
![Page 96: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/96.jpg)
CIPN-20 Sensory Neuropathy Scores, Segregated by Cycle-1 P-APS Scores
(Q 3 Weeks)100
0
40
50
60
70
80
90
Weeks
CIP
N-2
0 Se
nsor
y Sc
ores
P-APS score 1-4
P-APS score 0
0 6 9 12 15 183
P-APS score 5-6
P-APS score 7-10
![Page 97: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/97.jpg)
Topics
• Natural history investigation results
• Important clinical study results
![Page 98: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/98.jpg)
Selected CIPN Clinical Trials
• Gabapentin
• Duloxetine
CP1347589-98
![Page 99: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/99.jpg)
Is your practice commonly using gabapentin or pregabalin
for pts with CIPN?
1. Yes
2. No
![Page 100: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/100.jpg)
Efficacy of Gabapentin in the Management of Chemotherapy-Induced Peripheral Neuropathy: A
Phase 3 Randomized, Double-Blind, Placebo-Controlled, Crossover Trial (N00C3)
Rao R, Michalak J, Sloan J, Loprinzi C, Soori G, Nikcevich D, Warner D,
Novotny P, Kutteh L, Wong G
Cancer 110(9):2110, 2007Cancer 110(9):2110, 2007
CP1347589-100
![Page 101: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/101.jpg)
Study Schema
R
6 wk6 wk GabapentinGabapentin2700 mg/day2700 mg/day
PlaceboPlacebo
6 wk6 wk PlaceboPlaceboGabapentinGabapentin2700 mg/day2700 mg/day
2 wk2 wk WashoutWashout
Chemotherapy-induced neuropathyChemotherapy-induced neuropathy
CP1347589-101Cancer 110(9):2110, 2007Cancer 110(9):2110, 2007
![Page 102: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/102.jpg)
0
2
4
6
8
10
0 2 4 6 8 10 12 14
Placebo
Gabapentin
Meanpain
intensity
Meanpain
intensity
WeekWeek
P=0.21P=0.21 P=0.37P=0.37
First periodFirst periodWash-
outWash-
out Second periodSecond period
Mean Pain IntensityMean Pain Intensity
CP1347589-102
Placebo
Gabapentin
Cancer 110(9):2110, 2007Cancer 110(9):2110, 2007
![Page 103: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/103.jpg)
Pregabalin to Prevent the Paclitaxel Associated Acute Pain Syndrome and
CIPN
Patients receiving paclitaxel
chemotherapy
RPregabalin
PlaceboS
![Page 104: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/104.jpg)
Selected CIPN Clinical Trials
• Gabapentin
• Duloxetine
CP1347589-104
![Page 105: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/105.jpg)
CALGB 170601A Phase III Double Blind Trial of Oral
Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced
Peripheral Neuropathy (CIPN)
Principal Investigator: Ellen Lavoie Smith, PhD, APRN, AOCN®
Co-Investigators: Herbert Pang, PhD; Constance Cirrincione, MS; Stewart Fleishman, MD; Electra D. Paskett, PhD; Tim Ahles, PhD; Camilo Fadul, MD; Chetaye Knox; Charles L. Shapiro, MD
Trial Registration Number: NCT00489411
Supported by the NCI Division of Cancer Prevention & Lilly Pharmaceuticals
![Page 106: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/106.jpg)
Study ObjectivesPrimary Objective• To assess whether duloxetine 60mg daily
decreases CIPN-related neuropathic pain caused by paclitaxel or oxaliplatin
Secondary Objectives• To assess treatment-related side effects• To determine duloxetine’s influence on functional
status and quality of life
![Page 107: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/107.jpg)
Pain Outcomes
1 2 3 4 5 6
3.0
3.5
4.0
4.5
5.0
5.5
6.0
Mean Pain Score with SE During Initial Rx Period By Arm
Weeks
Mea
n
Duloxetine* -> PlaceboPlacebo* -> Duloxetine
1 2 3 4 5 6
18
20
22
24
26
28
30
32
Weeks
Mea
n
DuloxetinePlacebo
Aver
age
Pai
n In
terfe
renc
e
Mea
n P
ain
Sco
re
p = 0.003 Effect Size = 0.513
N = 220
p = 0.015
BPI-SF Pain Interference Score = sum of 7 items: interference with general activity, mood,
walking, normal work, relations with people, sleep, and enjoyment of life.
![Page 108: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/108.jpg)
Pain Reduction
![Page 109: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/109.jpg)
Most Common AEs – Initial Rx
%
![Page 110: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/110.jpg)
Take-Home Points• Newer antidepressants, gabapentin, and
progestational agents decrease hot flashes
• Don’t mix tamoxifen and paroxetine• Patients prefer venlafaxine over
gabapentin• Vaginal dryness: DHEA looks promising
![Page 111: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/111.jpg)
Take-Home Points• AI arthralgias: acupuncture, vitamin D, an
omega 3 F. A., and a testosterone preparation being explored
• P-APS appears to be of neurologic origin• Gabapentin was not helpful for treating
CIPN in a prospective randomized trial• Pregabalin is being studied for prevention
of the P-APS• Duloxetine of some help for CIPN
![Page 112: Symptom Management of Therapy-Related Toxicities](https://reader031.vdocument.in/reader031/viewer/2022012519/6194299fc80f305ce07cde01/html5/thumbnails/112.jpg)
CP1347589-112